Discover IPOPI’s newest leaflet on Secondary Immunodeficiencies (SIDs). Designed for patients, caregivers, and healthcare professionals, this educational tool aims to increase understanding of SIDs — an often under-recognised area of immune health. Through clear explanations and practical guidance, the leaflet educates readers on what SIDs are, the challenges of diagnosing and managing SIDs, and their […]
We extend our heartfelt thanks to everyone who made IPIC2025 an unforgettable success! With over 900 attendees, IPIC2025 was a truly inspiring gathering of our global community—filled with learning, collaboration, and shared commitment to advancing care for people with primary immunodeficiencies. As we close this remarkable chapter, we are already looking ahead with excitement to our […]
IPOPI has welcomed the positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). The opinion recommends granting marketing authorisation in the European Union for Waskyra™, a groundbreaking ex vivo gene therapy for Wiskott-Aldrich Syndrome (WAS), a rare and life-threatening primary immunodeficiency. “This marks a significant milestone […]
In 2024, IPOPI continued to bring the global PID community together — connecting patients, experts, and advocates across 75 countries to improve lives and drive progress in care and diagnosis for people with primary immunodeficiencies (PIDs). Highlights included the XVIII Global Patients’ Meeting in Marseille, new advocacy initiatives on plasma access and newborn screening, and […]
